CHIP functions as a novel suppressor of tumour angiogenesis with prognostic significance in human gastric cancer

Gut

Volumn 62, Issue 4, 2013, Pages 496-508

  Wang, Shouyu ^a   Wu, Xuming ^a,b   Zhang, Jianbing ^a,b   Chen, Yansu ^a   Xu, Jin ^a   Xia, Xiaowei ^a   He, Song ^b   Qiang, Fulin ^b   Li, Aiping ^a   Shu, Yongqian ^c   Røe, Oluf Dimitri ^d,e   Li, Gang ^f   Zhou, Jianwei W ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b Nantong Cancer Hospital   (China)

^c THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^d NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^e Levanger Hospital   (Norway)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXY TERMINUS OF HSC70 INTERACTING PROTEIN; CD31 ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; MATRIGEL; PROTEASOME; TRANSCRIPTION FACTOR RELA; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

ADULT; AGED; ANCHORAGE INDEPENDENT GROWTH; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER PROGNOSIS; CANCER TISSUE; CARCINOGENICITY; COHORT ANALYSIS; CONTROLLED STUDY; DRUG TARGETING; ENDOTHELIUM CELL; FEMALE; GROWTH INHIBITION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; STOMACH CANCER; STOMACH CARCINOGENESIS; SURVIVAL TIME; TISSUE MICROARRAY; TUMOR VASCULARIZATION; UBIQUITINATION;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL ADHESION; CELL LINE, TUMOR; CELL SURVIVAL; DNA METHYLATION; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-8; LUCIFERASES; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; NF-KAPPA B; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REAL-TIME POLYMERASE CHAIN REACTION; ROC CURVE; STATISTICS, NONPARAMETRIC; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION;

EID: 84874658997     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2011-301522     Document Type: Article

References (49)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108. (Pubitemid 40372904)
2. Yoo CH, Noh SH, Shin DW, et al. Recurrence following curative resection for gastric carcinoma. Br J Surg 2000;87:236-42. (Pubitemid 30088655)
3. Marrelli D, Roviello F, De Stefano A, et al. Risk factors for liver metastases after curative surgical procedures for gastric cancer: a prospective study of 208 patients treated with surgical resection. J Am Coll Surg 2004;198:51-8. (Pubitemid 38201088)
4. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66. (Pubitemid 46148091)
5. Hynes RO. Metastatic potential: generic predisposition of the primary tumor or rare, metastatic variants-or both? Cell 2003;113:821-3. (Pubitemid 36792026)
6. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
7. Tabernero J, Macarulla T, Ramos FJ, et al. Novel targeted therapies in the treatment of gastric and esophageal cancer. Ann Oncol 2005;16:1740-8. (Pubitemid 41637612)
8. Baldwin AS Jr. Series introduction: the transcription factor NF-kappaB and human disease. J Clin Invest 2001;107:3-6.
9. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006;441:431-6. (Pubitemid 44050137)
10. Karin M, Cao Y, Greten FR, et al. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002;2:301-10. (Pubitemid 37328783)
11. Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest 2001;107:241-6. (Pubitemid 32157954)
12. Tak PP, Firestein GS. NF-kappaB: a key role in inflammatory diseases. J Clin Invest 2001;107:7-11. (Pubitemid 32047405)
13. Hayden MS, Ghosh S. Shared principles in NF-kappaB signaling. Cell 2008;132:344-62.
14. Saccani S, Marazzi I, Beg AA, et al. Degradation of promoter-bound p65/RelA is essential for the prompt termination of the nuclear factor kappaB response. J Exp Med 2004;200:107-13. (Pubitemid 38924733)
15. Ryo A, Suizu F, Yoshida Y, et al. Regulation of NF-kappaB signaling by Pin1-dependent prolyl isomerization and ubiquitin-mediated proteolysis of p65/RelA. Mol Cell 2003;12:1413-26. (Pubitemid 38037011)
16. Nihira K, Ando Y, Yamaguchi T, et al. Pim-1 controls NF-kappaB signalling by stabilizing RelA/p65. Cell Death Differ 2010;17:689-98.
17. Tanaka T, Grusby MJ, Kaisho T. PDLIM2-mediated termination of transcription factor NF-kappaB activation by intranuclear sequestration and degradation of the p65 subunit. Nat Immunol 2007;8:584-91. (Pubitemid 46785122)
18. Thoms HC, Loveridge CJ, Simpson J, et al. Nucleolar targeting of RelA (p65) is regulated by COMMD1-dependent ubiquitination. Cancer Res 2010;70:139-49.
19. Esser C, Alberti S, Hohfeld J. Cooperation of molecular chaperones with the ubiquitin/proteasome system. Biochim Biophys Acta 2004;1695:171-88. (Pubitemid 39574972)
20. Connell P, Ballinger CA, Jiang J, et al. The co-chaperone CHIP regulates protein triage decisions mediated by heat-shock proteins. Nat Cell Biol 2001;3:93-6. (Pubitemid 32114838)
21. Muller P, Hrstka R, Coomber D, et al. Chaperone-dependent stabilization and degradation of p53 mutants. Oncogene 2008;27:3371-83. (Pubitemid 351769319)
22. Fan M, Park A, Nephew KP. CHIP (carboxyl terminus of Hsc70-interacting protein) promotes basal and geldanamycin-induced degradation of estrogen receptor-alpha. Mol Endocrinol 2005;19:2901-14. (Pubitemid 41697710)
23. Xu W, Marcu M, Yuan X, et al. Chaperone-dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2/Neu. Proc Natl Acad Sci U S A 2002;99:12847-52.
24. Kamynina E, Kauppinen K, Duan F, et al. Regulation of proto-oncogenic dbl by chaperone-controlled, ubiquitin-mediated degradation. Mol Cell Biol 2007;27:1809-22.
25. Xin H, Xu X, Li L, et al. CHIP controls the sensitivity of transforming growth factorbeta signaling by modulating the basal level of Smad3 through ubiquitin-mediated degradation. J Biol Chem 2005;280:20842-50. (Pubitemid 40776789)
26. Bento CF, Fernandes R, Ramalho J, et al. The chaperone-dependent ubiquitin ligase CHIP targets HIF-1alpha for degradation in the presence of methylglyoxal. PLoS One 2010;5:e15062.
27. Shang Y, Zhao X, Xu X, et al. CHIP functions an E3 ubiquitin ligase of Runx1. Biochem Biophys Res Commun 2009;386:242-6.
28. Jang KW, Lee JE, Kim SY, et al. The C-terminus of Hsp70-interacting protein promotes Met receptor degradation. J Thorac Oncol 2011;6:679-87.
29. Kajiro M, Hirota R, Nakajima Y, et al. The ubiquitin ligase CHIP acts as an upstream regulator of oncogenic pathways. Nat Cell Biol 2009;11:312-19.
30. Jan CI, Yu CC, Hung MC, et al. Tid1, CHIP and ErbB2 interactions and their prognostic implications for breast cancer patients. J Pathol 2011;225:424-37.
31. Weichert W, Roske A, Gekeler V, et al. Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. Lancet Oncol 2008;9:139-48.
32. Wang S, Gong Z, Chen R, et al. JWA regulates XRCC1 and functions as a novel base excision repair protein in oxidative-stress-induced DNA single-strand breaks. Nucleic Acids Res 2009;37:1936-50.
33. Bai J, Zhang J, Wu J, et al. JWA regulates melanoma metastasis by integrin alphaVbeta3 signaling. Oncogene 2010;29:1227-37.
34. Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 2000;56:337-44. (Pubitemid 30422619)
35. Hatakeyama S, Yada M, Matsumoto M, et al. U box proteins as a new family of ubiquitin-protein ligases. J Biol Chem 2001;276:33111-20.
36. Weidner N, Semple JP, Welch WR, et al. Tumor angiogenesis and metastasisdcorrelation in invasive breast carcinoma. N Engl J Med 1991;324:1-8.
37. Zagouri F, Papadimitriou CA, Dimopoulos MA, et al. Molecularly targeted therapies in unresectable-metastatic gastric cancer. A systematic review. Cancer Treat Rev 2011;37:599-610.
38. Weidner N. Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol 1995;147:9-19.
39. Kashima L, Toyota M, Mita H, et al. CHFR, a potential tumor suppressor, downregulates interleukin-8 through the inhibition of NF-kappaB. Oncogene 2009;28:2643-53.
40. Kalluri R. Basement membranes: structure, assembly and role in tumour angiogenesis. Nat Rev Cancer 2003;3:422-33. (Pubitemid 37328846)
41. Garkavtsev I, Kozin SV, Chernova O, et al. The candidate tumour suppressor protein ING4 regulates brain tumour growth and angiogenesis. Nature 2004;428:328-32. (Pubitemid 38418804)
42. Nurnberg W, Tobias D, Otto F, et al. Expression of interleukin-8 detected by in situ hybridization correlates with worse prognosis in primary cutaneous melanoma. J Pathol 1999;189:546-51.
43. Cuenca RE, Azizkhan RG, Haskill S. Characterization of GRO alpha, beta and gamma expression in human colonic tumours: potential significance of cytokine involvement. Surg Oncol 1992;1:323-9.
44. Smith DR, Polverini PJ, Kunkel SL, et al. Inhibition of interleukin 8 attenuates angiogenesis in bronchogenic carcinoma. J Exp Med 1994;179:1409-15. (Pubitemid 24129558)
45. Lee KH, Bae SH, Lee JL, et al. Relationship between urokinase-type plasminogen receptor, interleukin-8 gene expression and clinicopathological features in gastric cancer. Oncology 2004;66:210-17. (Pubitemid 38813048)
46. Sparmann A, Bar-Sagi D. Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 2004;6:447-58. (Pubitemid 39469981)
47. Arenzana-Seisdedos F, Thompson J, Rodriguez MS, et al. Inducible nuclear expression of newly synthesized I kappa B alpha negatively regulates DNA-binding and transcriptional activities of NF-kappa B. Mol Cell Biol 1995;15:2689-96.
48. Arenzana-Seisdedos F, Turpin P, Rodriguez M, et al. Nuclear localization of I kappa B alpha promotes active transport of NF-kappa B from the nucleus to the cytoplasm. J Cell Sci 1997;110:369-78. (Pubitemid 27095656)
49. Li X, Huang M, Zheng H, et al. CHIP promotes Runx2 degradation and negatively regulates osteoblast differentiation. J Cell Biol 2008;181:959-72. (Pubitemid 351846829)